

Click For [Full Prescribing Information](#) including **BOXED WARNING**, if applicable.

Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045



October 31, 2022

**Availability Update for Nipent™ (pentostatin for injection) 10 mg Single Dose
ONCO-TAIN™ Glass Fliptop Vial**

Dear Customer,

In late January, Pfizer Hospital provided an update regarding a supply interruption for **Nipent™ (pentostatin for injection) 10 mg Single Dose ONCO-TAIN™ Glass Fliptop Vial** due to a manufacturing delay for the Active Pharmaceutical Ingredient (API), which is supplied by a third-party manufacturer. Although the root cause has been identified, the delay has resulted in a longer-than-anticipated limited supply and likely stockout. The U.S. Food and Drug Administration (FDA) has been notified, and Pfizer has been coordinating closely with our API supplier.

Pfizer anticipates next deliveries of Nipent (pentostatin for injection) to resume by January 2023, with full recovery—when we have sufficient inventory available to meet historical demand projections, in addition to several weeks of safety stock in our distribution centers—by the end of Q1 2023. During this interim period, understanding the importance of this product to patients and health care professionals, Pfizer is taking the following proactive steps to delay the temporary stockout and ensure that all available inventory is distributed in accordance with our medical reserve process:

- Nipent™ (pentostatin for injection) 10 mg Single Dose ONCO-TAIN™ Glass Fliptop Vial inventory in Pfizer's distribution centers will be available for direct shipment only. However, customers should first check with local wholesalers and within their hospital system for any potential remaining inventory before requesting a direct order.
- Pfizer will distribute available inventory in accordance with its medical reserve process, which requires that customers complete a medical reserve request form to request product on a per patient basis.
- The attached medical reserve request form must be completed by the institution and authorized and emailed by the treating Health Care Provider or Director of Pharmacy (or above) on a per patient basis to receive product.
- Completed forms should be emailed to PIAllocationInquiry@pfizer.com.
- Requests will be reviewed and filled in the order they are received and only with the required documentation. Cut off time for overnight requests is 3 p.m. (CT).

Pfizer will notify customers as soon as supply is recovered and the medical reserve process is lifted. In addition, we encourage you to check our [Availability Report](#), updated frequently and accessible on the PfizerHospitalUS.com homepage, for the latest information on product status.

Click For [Full Prescribing Information](#) including **BOXED WARNING**, if applicable.

Thank you for your patience as we work through this supply situation. During this interim period, for additional product availability questions, please reach out to your Pfizer Hospital sales representative or account executive. Alternatively, the Supply Continuity Team can be contacted between 7 a.m. and 6 p.m. (CT) at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]). For medical inquiries, please contact Pfizer Medical Information at 1-800-438-1985.

Thank you,

Daniel Hrlic
Director, Oncology and Alternate Site
Pfizer Hospital U.S.